CN1318080C - Medicine used for treating osteonecrosis, femur ischemic osteonecrosis - Google Patents
Medicine used for treating osteonecrosis, femur ischemic osteonecrosis Download PDFInfo
- Publication number
- CN1318080C CN1318080C CNB2005100174818A CN200510017481A CN1318080C CN 1318080 C CN1318080 C CN 1318080C CN B2005100174818 A CNB2005100174818 A CN B2005100174818A CN 200510017481 A CN200510017481 A CN 200510017481A CN 1318080 C CN1318080 C CN 1318080C
- Authority
- CN
- China
- Prior art keywords
- portions
- medicine
- osteonecrosis
- radix
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 46
- 206010031264 Osteonecrosis Diseases 0.000 title claims abstract description 11
- 230000000302 ischemic effect Effects 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title description 19
- 210000000689 upper leg Anatomy 0.000 title 1
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 6
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 6
- 241000131808 Scolopendra Species 0.000 claims abstract description 6
- 241000522620 Scorpio Species 0.000 claims abstract description 6
- 239000009490 scorpio Substances 0.000 claims abstract description 6
- 239000002994 raw material Substances 0.000 claims abstract description 3
- 239000000203 mixture Substances 0.000 claims abstract 2
- 208000007875 Femur Head Necrosis Diseases 0.000 claims description 11
- 241000756943 Codonopsis Species 0.000 claims description 5
- 241001489978 Eupolyphaga Species 0.000 claims description 5
- 239000009636 Huang Qi Substances 0.000 claims description 5
- 241000283956 Manis Species 0.000 claims description 5
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 5
- 210000000582 semen Anatomy 0.000 claims description 5
- 241000255791 Bombyx Species 0.000 claims description 3
- 241001057584 Myrrha Species 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 abstract description 16
- 239000008280 blood Substances 0.000 abstract description 16
- 230000017531 blood circulation Effects 0.000 abstract description 10
- 210000000988 bone and bone Anatomy 0.000 abstract description 8
- 210000003734 kidney Anatomy 0.000 abstract description 5
- 230000005906 menstruation Effects 0.000 abstract description 4
- 231100000957 no side effect Toxicity 0.000 abstract description 2
- 208000024891 symptom Diseases 0.000 abstract description 2
- 241001127714 Amomum Species 0.000 abstract 1
- 241000213006 Angelica dahurica Species 0.000 abstract 1
- 241000255789 Bombyx mori Species 0.000 abstract 1
- 241000131329 Carabidae Species 0.000 abstract 1
- 241000007126 Codonopsis pilosula Species 0.000 abstract 1
- 240000007311 Commiphora myrrha Species 0.000 abstract 1
- 235000006965 Commiphora myrrha Nutrition 0.000 abstract 1
- 235000007265 Myrrhis odorata Nutrition 0.000 abstract 1
- 206010028851 Necrosis Diseases 0.000 abstract 1
- 244000236658 Paeonia lactiflora Species 0.000 abstract 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 abstract 1
- 241000283966 Pholidota <mammal> Species 0.000 abstract 1
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 241000270666 Testudines Species 0.000 abstract 1
- 240000003243 Thuja occidentalis Species 0.000 abstract 1
- 235000008109 Thuja occidentalis Nutrition 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 229940107666 astragalus root Drugs 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 230000006698 induction Effects 0.000 abstract 1
- 230000017074 necrotic cell death Effects 0.000 abstract 1
- 235000005412 red sage Nutrition 0.000 abstract 1
- 238000005728 strengthening Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 239000000843 powder Substances 0.000 description 12
- 210000003128 head Anatomy 0.000 description 10
- 230000001954 sterilising effect Effects 0.000 description 8
- 238000004659 sterilization and disinfection Methods 0.000 description 8
- 208000002193 Pain Diseases 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000036407 pain Effects 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 238000010298 pulverizing process Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 210000001624 hip Anatomy 0.000 description 3
- 210000004394 hip joint Anatomy 0.000 description 3
- 208000037920 primary disease Diseases 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 208000010392 Bone Fractures Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 206010017076 Fracture Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000037273 Pathologic Processes Diseases 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 229940121657 clinical drug Drugs 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 238000003305 oral gavage Methods 0.000 description 2
- 230000001354 painful effect Effects 0.000 description 2
- 230000009054 pathological process Effects 0.000 description 2
- 238000005498 polishing Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000003014 reinforcing effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- UUTKICFRNVKFRG-WDSKDSINSA-N (4R)-3-[oxo-[(2S)-5-oxo-2-pyrrolidinyl]methyl]-4-thiazolidinecarboxylic acid Chemical compound OC(=O)[C@@H]1CSCN1C(=O)[C@H]1NC(=O)CC1 UUTKICFRNVKFRG-WDSKDSINSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 206010002027 Amyotrophy Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 206010051728 Bone erosion Diseases 0.000 description 1
- 208000034657 Convalescence Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 241001446509 Psoralea Species 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 208000037873 arthrodesis Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 238000011981 development test Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000003648 hair appearance Effects 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 210000003692 ilium Anatomy 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000004409 osteocyte Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007119 pathological manifestation Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000001612 separation test Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 210000001694 thigh bone Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a medicine for treating osteonecrosis and ischemic necrosis of a femoral head, which is characterized in that the present invention is prepared by using raw materials in the following mixture proportions by weight: 102 to 105 portions of notoginseng, 98 to 104 portions of red sage root, 75 to 80 portions of ground beetle, 78 to 84 portions of prepared pangolin, 76 to 81 portions of myrrh, 75 to 80 portions of turtle shell, 50 to 55 portions of scorpio, 48 to 54 portions of batryticated silkworm, 50 to 55 portions of scolopendra, 48 to 54 portions of codonopsis pilosula, 50 to 55 portions of astragalus root, 47 to 52 portions of Chinese angelica root, 50 to 55 portions of white peony root, 48 to 54 portions of amomum fruit, 52 to 56 portions of rhizoma cyperi and 48 to 54 portions of arborvitae seed. The whole formula performs the functions of blood circulation activation, blood stasis dissipation, menstruation induction, menalgia relieving, kidney invigoration, bone strengthening and Qi and blood tonifying. The whole formula has the advantages of reasonable compatibility, medicine and symptom conformity, positive therapeutic effect and no side effect.
Description
Technical field
The present invention relates to a kind of Chinese patent medicine, relate to a kind of medicine that is used for the treatment of osteonecrosis, ischemic necrosis of femoral head specifically.
Background technology
Ischemic necrosis of femoral head is meant because the different causes of disease causes capital disturbance of blood circulation, makes femoral head that the pathological process of part or completeness ischemia take place.This patient is more common in 30-50 year, and has half to involve bilateral femoral head.Motherland's medical science is thought, ischemic necrosis of femoral head belongs to " osteomyelitis " category, its main pathogenesis is that caused by liver and kidney deficiency, qi depression to blood stasis, bone lose and moisten fosterly, or hindered by violence, or the infection excessive QI, or sexual strain, or the natural endowment deficiency, its clinical manifestation is symptoms such as the hip arthralgia, limping, function limitation, lower limb muscles atrophy, until the forfeiture self care ability, its course of disease is long, disability rate is high, brings huge misery to the patient.
Femur head necrosis has become current orthopaedics commonly encountered diseases, also is one of world's orthopaedics three big difficult and complicated illness.Owing to after the collapse of the femoral head distortion, often cause the hip joint handicap, therefore more and more be subjected to the attention of medical circle.At present, the comparatively popular method of western medical treatment primary disease mainly is an operative treatment, and be broadly divided into following two classes: (1) improves the femoral head blood supply: implement synovectomy, core decompression art, vessel pedicle ilium transplantation, vascular bundle implantation; (2) improve the mortar head and contain, improve the femoral head at weight loading position: as distinguishing osteotomy, shelf operation of hip joint between the femoral head rotor.Other is also being accepted by people gradually as artificial femoral head replacement, replacement of total hip, arthrodesis etc.Above-mentioned various operation all is to reach different curative effects by different means, and clinical manifestation is that the patient is movable better, ambulation in early days, and the hospital stays is shorter.But postoperative is prone to complication such as collapse of the femoral head, the loosening dislocation of artificial thigh bone, cervical region fracture and infection, and is difficult to remedy.Therefore, the patient has doubt more before the art, even can suffer that the patient refuses.
Modern medicine is thought: femur head necrosis is the downright bad caused pathological process of active component (osteocyte, medullary cell and adipose cell) of bone, but up to the present still can not determine the definite reason that causes primary disease.General think relevant with the wound of hip joint, some drugs (as adrenocortical hormone), multiple disease, chronic alcoholism etc. more.The common pathological manifestations of femur head necrosis is the unusual of the femoral head disturbance of blood circulation that caused by a variety of causes and joint stress.Motherland's medical science extensive knowledge and profound scholarship, aboundresources, people-oriented, utilizes motherland's traditional medicine, adopts the non-operative treatment ischemic necrosis of femoral head, and expense is lower, and no pain, and treating both the principal and secondary aspects of a disease has caused the great attention of medical circle in recent years, and has obtained gratifying achievement.Clinical pharmacology studies show that: Chinese medicine is applicable to the overall process of primary disease treatment, and its effect comprises the blood circulation that improves bone, and blood flow increasing reduces intra-osteal pressure, and anticoagulant alleviates the osteonecrosis degree, promotes effects such as osteonecrosis reparation.Current research finds that also Chinese medicine also has the angiogenic growth of promotion and the effect of protection circulation.
Summary of the invention
Purpose of the present invention provides a kind of just on the basis of above-mentioned Chinese medicine research be the medicine that is used for the treatment of osteonecrosis, ischemic necrosis of femoral head of the rule of treatment with blood circulation promoting and blood stasis dispelling, inducing menstruation to relieve menalgia, reinforcing the kidney to strengthen the bone.
Purpose of the present invention can realize by following measure:
Raw materials of effective components is formed and weight portion is in the medicine that is used for the treatment of osteonecrosis, ischemic necrosis of femoral head of the present invention: wherein: Radix Notoginseng 102-105 part, Radix Salviae Miltiorrhizae 98-104 part, Eupolyphaga Seu Steleophaga 75-80 part, Squama Manis (processed) 78-84 part, Myrrha 76-81 part, Carapax Trionycis 75-80 part, Scorpio 50-55 part, Bombyx Batryticatus 48-54 part, Scolopendra 50-55 part, Radix Codonopsis 48-54 part, Radix Astragali 50-55 part, Radix Angelicae Sinensis 47-52 part, Radix Paeoniae Alba 50-55 part, Fructus Amomi 48-54 part, Rhizoma Cyperi 52-56 part, Semen Platycladi 48-54 part.
Prescription analysis of the present invention is as follows:
Eupolyphaga Seu Steleophaga, salty, cold, go into Liver Channel, removing blood stasis is treated folding and is hindered amplification on Canon of Materia Medica day: " treating the effect that folding is hindered dissipating blood stasis blood "; Carapax Trionycis, nourishing YIN and clearing away heat, hard masses softening and resolving; Myrrha is used for blockage of menstruation; Radix Notoginseng, hemostasis dissipating blood stasis, analgesia; Scorpio, endogenous wind stopping relieving convulsion, activating collaterals to relieve pain, detoxicating and resolving stagnation of pathogens.The above five tastes are monarch drug.Bombyx Batryticatus, expelling wind and clearing away heat, relieving convulsion reducing phlegm; Scolopendra, the spasmolytic wind that looses, removing toxic substances and promoting subsidence of swelling; Squama Manis, promoting blood circulation to remove blood stasis, latus rectum, reducing swelling and alleviating pain; Semen Platycladi, Radix Salviae Miltiorrhizae, blood circulation promoting and blood stasis dispelling, expelling pathogenic wind and eliminating dampness, tonifying liver is supported kidney, strong muscles and bones, removing heat from blood disappears bitterly, and this five kinds of Chinese medicine is a ministerial drug.Radix Codonopsis, air making-up and spleen enlivening is with the source of helping life; The Radix Paeoniae Alba, is slightly cold at bitter in the mouth, acid, goes into Liver Channel; The Radix Astragali, QI invigorating, consolidating superficial resistance, granulation promoting; Radix Angelicae Sinensis, benefiting blood and regulating blood circulation, menstruction regulating and pain relieving, this four Chinese medicine are adjuvant drug altogether.Fructus Amomi, Rhizoma Cyperi, spleen invigorating, treating blood disorders gas is messenger drug.
Take a broad view of full side, blood circulation promoting and blood stasis dispelling, fills blood at inducing menstruation to relieve menalgia, reinforcing the kidney to strengthen the bone, and compatibility is reasonable, and the medicine card conforms to, and curative effect is certain, has no side effect.
Clinical drug of the present invention is observed and is tested as follows:
Clinical observation: 100 examples.
Clinical manifestation: local red and swollen, twinge, painful have the place of deciding, becoming severe at night, complexion is dark, and hair quality is dark red, deep pulse, tcm diagnosis is a qi stagnation and blood stasis type.Western medicine diagnose is a local pain, or radiated pain; Waist is to strong lateral bending song: " 4 " word is levied (+); The pelvis separation test positive; Amyotrophy; X-ray film, CT sheet show the clinical manifestation of fracture, osteonecrosis.
The present invention is according to conditions of patients, cooperate and select bone erosion renewel pill, Psoralea pill and the bone impediment convalescence capsule of separate case application for use, clinical efficacy shows: obey patient's day three times, each 6 grams, being aided with other medicines simultaneously took 480 days continuously, per 80 days is a course of treatment, and tracing observation statistics total effective rate is 94%.With state of an illness weight branch: I phases 18 row, effective percentage 100%; II phases 39 example, effective percentage 96%; III phases 31 example, effective percentage 93.5%; IV phases 12 example, effective percentage 75%.
Great new medicine science and technology development test result is as follows through Henan for the drug effect of medicine of the present invention, acute toxicity test:
Acute toxicity test: with medicine of the present invention be equivalent to clinical medicine 133 extraordinarily pure water be mixed with suspension, give mouse stomach, a continuous week observes, outward appearance, action activity, the mental status, diet, drinking-water, feces, fur, the colour of skin, breathing are all normal, the no abnormal secretions in nose, eye and oral cavity, acute toxic reaction and death do not appear, healthy survival.
Long term toxicity test: with medicine of the present invention be equivalent to clinical medicine 50～30 extraordinarily pure water be mixed with suspension, give rat oral gavage, 3 months test periods (clinical 1 month) observe, the figure does not have pathology and changes, and slowness toxicity do not occur and changes.
The test of pesticide effectiveness: be mice, rat paw, ears, blood capillary, the administration respectively of two axil otch, cause inflammation, pain and swelling etc., with clinical drug dosage of the present invention 10～20 extraordinarily pure water be mixed with suspension, give rat oral gavage, with be equivalent to the clinical application amount 12.5～25 extraordinarily pure water be mixed with suspension, give mouse stomach, observed in continuous 7 days, prove that medicine of the present invention has tangible detumescence, antiinflammatory, the painful effect in town.
The specific embodiment
The present invention does with detailed description below with reference to embodiment:
Embodiment 1:
Present embodiment adopts following proportioning and processing step to realize:
Divide two groups of processing levigations with ten Six-element medicines.
First group: get Radix Notoginseng 102g by weight, Eupolyphaga Seu Steleophaga 80g, Squama Manis (processed) 78g, Carapax Trionycis 78g, Scorpio 50g, Scolopendra 54g Six-element is pulverized with pulverizer and is ground into fine powder, sieves, flour extraction is 96%～98%, drug powder after will pulverizing afterwards carries out sterilization treatment with 100 ℃ of flowing steams, its time was controlled between 25～40 minutes, make antibacterial by 10000-100000/g reduce to 500/below the g, mycete by 1000-1500/g reduce to 100/below the g, drug powder seal storage after the sterilization treatment, standby;
Second group: get Radix Codonopsis 54g by weight, Radix Astragali 50g, Radix Angelicae Sinensis 50g, Radix Paeoniae Alba 55g, Fructus Amomi 50g, Rhizoma Cyperi 52g, Semen Platycladi 50g pulverizes, sieves with pulverizer, and the drug powder after will pulverizing afterwards carries out sterilization treatment with 100 ℃ of flowing steams, its time was controlled between 25～40 minutes, make antibacterial by 10000-100000/g reduce to 500/below the g, mycete by 1000-1500/g reduce to 100/below the g, the drug powder seal storage after the sterilization treatment;
Above-mentioned two groups of drug powders are placed in fully mixing in the mixer, add pure water and make the watered pill, irregular parts such as dispersion, distortion are removed in oven dry, upward even Pulvis Talci, and the active carbon coating with more than granularity 120 orders is patent medicine after the polishing.
Embodiment 2:
Present embodiment adopts following proportioning and processing step to realize:
Divide two groups of processing levigations with ten Six-element medicines.
First group: get Radix Notoginseng 105g by weight, Eupolyphaga Seu Steleophaga 78g, Squama Manis (processed) 84g, Carapax Trionycis 80g, Scorpio 54g, Scolopendra 50g Six-element is pulverized with pulverizer and is ground into fine powder, sieves, flour extraction is 96%～98%, drug powder after will pulverizing afterwards carries out sterilization treatment with 100 ℃ of flowing steams, its time was controlled between 25～40 minutes, make antibacterial by 10000-100000/g reduce to 500/below the g, mycete by 1000-1500/g reduce to 100/below the g, drug powder seal storage after the sterilization treatment, standby;
Second group: get Radix Codonopsis 50g by weight, Radix Astragali 54g, Radix Angelicae Sinensis 48g, Radix Paeoniae Alba 50g, Fructus Amomi 54g, Rhizoma Cyperi 55g, Semen Platycladi 54g pulverizes, sieves with pulverizer, drug powder after will pulverizing afterwards carries out sterilization treatment with 100 ℃ of flowing steams, its time was controlled between 25～40 minutes, make antibacterial by 10000-100000/g reduce to 500/below the g, mycete by 1000-1500/g reduce to 100/below the g, drug powder seal storage after the sterilization treatment, standby;
Above-mentioned two groups of drug powders are placed in fully mixing in the mixer, add pure water and make the watered pill, irregular parts such as dispersion, distortion are removed in oven dry, upward even Pulvis Talci, and the active carbon coating with more than granularity 120 orders is patent medicine after the polishing.
Claims (1)
1, a kind of medicine that is used for the treatment of osteonecrosis, ischemic necrosis of femoral head, it is characterized in that: raw materials of effective components composition and weight portion thereof are in this medicine: Radix Notoginseng 102-105 part, Radix Salviae Miltiorrhizae 98-104 part, Eupolyphaga Seu Steleophaga 75-80 part, Squama Manis (processed) 78-84 part, Myrrha 76-81 part, Carapax Trionycis 75-80 part, Scorpio 50-55 part, Bombyx Batryticatus 48-54 part, Scolopendra 50-55 part, Radix Codonopsis 48-54 part, Radix Astragali 50-55 part, Radix Angelicae Sinensis 47-52 part, Radix Paeoniae Alba 50-55 part, Fructus Amomi 48-54 part, Rhizoma Cyperi 52-56 part, Semen Platycladi 48-54 part.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100174818A CN1318080C (en) | 2005-04-01 | 2005-04-01 | Medicine used for treating osteonecrosis, femur ischemic osteonecrosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100174818A CN1318080C (en) | 2005-04-01 | 2005-04-01 | Medicine used for treating osteonecrosis, femur ischemic osteonecrosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1686216A CN1686216A (en) | 2005-10-26 |
| CN1318080C true CN1318080C (en) | 2007-05-30 |
Family
ID=35304258
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100174818A Expired - Fee Related CN1318080C (en) | 2005-04-01 | 2005-04-01 | Medicine used for treating osteonecrosis, femur ischemic osteonecrosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1318080C (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1215611A (en) * | 1998-10-22 | 1999-05-05 | 柴玉楼 | Medicine for treatment of ischemic necrosis of fermoral head |
| CN1544056A (en) * | 2003-11-26 | 2004-11-10 | 李宝仓 | Oral medicine for treating ischemic necrosis of femoral head and its preparation |
| CN1579478A (en) * | 2003-10-01 | 2005-02-16 | 李天宇 | Capsule for treating osteonecrosis and bone fracture |
-
2005
- 2005-04-01 CN CNB2005100174818A patent/CN1318080C/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1215611A (en) * | 1998-10-22 | 1999-05-05 | 柴玉楼 | Medicine for treatment of ischemic necrosis of fermoral head |
| CN1579478A (en) * | 2003-10-01 | 2005-02-16 | 李天宇 | Capsule for treating osteonecrosis and bone fracture |
| CN1544056A (en) * | 2003-11-26 | 2004-11-10 | 李宝仓 | Oral medicine for treating ischemic necrosis of femoral head and its preparation |
Non-Patent Citations (1)
| Title |
|---|
| 骨复生胶囊治疗早期激素性股骨头缺血坏死的临床研究 李毅等，山东中医药大学学报，第28卷第1期 2004 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1686216A (en) | 2005-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101138623A (en) | Medicament for preventing and treating deficiency of the kidney essence | |
| CN103127326A (en) | Pharmaceutical composition for treating osteoarthritis and preparation method thereof | |
| CN101897879B (en) | Traditional Chinese medicine for treating rheumatic arthritis | |
| CN103977281A (en) | Traditional Chinese medicine composition for treating female endocrine disorders and preparation method thereof | |
| CN112494606A (en) | Traditional Chinese medicine composition for treating arthralgia, myalgia and rheumatic pain and preparation method and application thereof | |
| CN1318080C (en) | Medicine used for treating osteonecrosis, femur ischemic osteonecrosis | |
| CN104800443A (en) | Bone setting agent with functions of tonifying kidney and regenerating bone marrow | |
| CN105169279A (en) | Traditional Chinese medicine composition for treating knee joint bone hyperplasia | |
| CN104161805B (en) | A kind of Chinese medicine that treating caput femoris necrosis and preparation method | |
| CN1320900C (en) | Bone erosion renewel pill | |
| CN102836276B (en) | Bone spur softening pill for treating osteoarthritis | |
| CN102743499B (en) | Chinese medicinal herb drug for treating soft tissue internal injury blood stasis and cerebral hemorrhage and method for preparing same | |
| CN1270741C (en) | Psoralea pill | |
| CN106361981A (en) | Traditional Chinese medicine with effects of nourishing yin and strengthening yang | |
| CN101239140A (en) | Chinese medicine for treating psoriasis | |
| CN107617081B (en) | Traditional Chinese medicine composition for treating alopecia and preparation method thereof | |
| CN1270730C (en) | Channels sootheing and network vessel quickening pill for treating protrasion of lumbar intervertebral disci | |
| CN104984049A (en) | Traditional Chinese medicine capsule for treating severe acute pancreatitis | |
| CN1175881C (en) | Medicine for treating ischemic necrosis of head of femur and preparation method thereof | |
| CN117338851B (en) | Traditional Chinese medicine composition for treating diabetic peripheral neuropathy, preparation method and application | |
| CN1270749C (en) | Bone impediment convalescence capsule | |
| CN102949601B (en) | Medicine for treating alopecia areata and preparation method thereof | |
| CN113730525A (en) | Traditional Chinese medicine composition for treating postmenopausal osteoporosis and application thereof | |
| CN119909137A (en) | A Chinese medicine composition, preparation and application for treating kidney-essence deficiency type bone atrophy | |
| CN1183918C (en) | Medicine for curing protrution of intervetebral disc and its preparing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070530 |